{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:37:23Z","timestamp":1789663043119,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03225-4","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T07:46:20Z","timestamp":1748504780000},"page":"3528-3546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mobility and Quality of Life in Children with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3350-9896","authenticated-orcid":false,"given":"Raja","family":"Padidela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7263-8546","authenticated-orcid":false,"given":"Nick","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-3601","authenticated-orcid":false,"given":"Paul","family":"Arundel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7019-5647","authenticated-orcid":false,"given":"Shona","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Zygouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8603-5663","authenticated-orcid":false,"given":"M. Zulf","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-4144","authenticated-orcid":false,"given":"Nick","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-8942","authenticated-orcid":false,"given":"Vrinda","family":"Saraff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"3225_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","volume":"102","author":"MP Whyte","year":"2017","unstructured":"Whyte MP. Hypophosphatasia: an overview for 2017. Bone. 2017;102:15\u201325. https:\/\/doi.org\/10.1016\/j.bone.2017.02.011.","journal-title":"Bone"},{"issue":"2","key":"3225_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.11138\/ccmbm\/2017.14.1.230","volume":"14","author":"F Conti","year":"2017","unstructured":"Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Miner Bone Metab. 2017;14(2):230\u20134. https:\/\/doi.org\/10.11138\/ccmbm\/2017.14.1.230.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"7410","key":"3225_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0140-6736(65)91422-4","volume":"2","author":"RG Russell","year":"1965","unstructured":"Russell RG. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet. 1965;2(7410):461\u20134. https:\/\/doi.org\/10.1016\/s0140-6736(65)91422-4.","journal-title":"Lancet"},{"issue":"suppl 2","key":"3225_CR4","first-page":"380","volume":"10","author":"C Rockman-Greenberg","year":"2013","unstructured":"Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(suppl 2):380\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"key":"3225_CR5","unstructured":"Fang S, Navaratnarajah N, Umeh E, Lyons J. Diagnosed prevalence of hypophosphatasia in the United States: a real-world analysis of electronic health records [poster A36]. In: Presented at: 39th international conference on pharmacoepidemiology and therapeutic risk management; 23\u201327 August 2023, Halifax, NS, Canada."},{"issue":"3","key":"3225_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1469-1809.2011.00642.x","volume":"75","author":"E Mornet","year":"2011","unstructured":"Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet. 2011;75(3):439\u201345. https:\/\/doi.org\/10.1111\/j.1469-1809.2011.00642.x.","journal-title":"Ann Hum Genet"},{"key":"3225_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2019.01.049","volume":"209","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Leung E, Wilcox WR, et al. Natural history of perinatal and infantile hypophosphatasia: a retrospective study. J Pediatr. 2019;209:116\u201324. https:\/\/doi.org\/10.1016\/j.jpeds.2019.01.049.","journal-title":"J Pediatr"},{"issue":"1","key":"3225_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","volume":"20","author":"W H\u00f6gler","year":"2019","unstructured":"H\u00f6gler W, Langman C, da Silva HG, et al. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20(1):80. https:\/\/doi.org\/10.1186\/s12891-019-2420-8.","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"3225_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"1366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR, Salman NJ, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia [with Supplementary Appendix]. N Engl J Med. 2012;1366(10):904\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1106173.","journal-title":"N Engl J Med"},{"issue":"7","key":"3225_CR10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","volume":"104","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, Harmatz P, Vockley J, et al. Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104(7):2735\u201347. https:\/\/doi.org\/10.1210\/jc.2018-02335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"3225_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.85971","volume":"1","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Madson KL, Phillips D, et al. Asfotase alfa therapy for children with hypophosphatasia [with On-line Only Supplement]. JCI Insight. 2016;1(9): e85971. https:\/\/doi.org\/10.1172\/jci.insight.85971.","journal-title":"JCI Insight"},{"issue":"1","key":"3225_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/jc.2015-3462","volume":"101","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Rockman-Greenberg C, Ozono K, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334\u201342. https:\/\/doi.org\/10.1210\/jc.2015-3462.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3225_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Simmons JH, Moseley S, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial [with Supplementary Appendix]. Lancet Diabetes Endocrinol. 2019;7(2):93\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(18)30307-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3225_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","volume":"166","author":"American Thoracic Society","year":"2002","unstructured":"American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137. https:\/\/doi.org\/10.1164\/ajrccm.166.1.at1102.","journal-title":"Am J Respir Crit Care Med"},{"key":"3225_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00003086-198109000-00015","volume":"159","author":"EE Bleck","year":"1981","unstructured":"Bleck EE. Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res. 1981;159:111\u201322.","journal-title":"Clin Orthop Relat Res"},{"issue":"3","key":"3225_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1067\/mpd.2000.107892","volume":"137","author":"RH Engelbert","year":"2000","unstructured":"Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs H, Helders PJ. Osteogenesis imperfecta in childhood: prognosis for walking. J Pediatr. 2000;137(3):397\u2013402. https:\/\/doi.org\/10.1067\/mpd.2000.107892.","journal-title":"J Pediatr"},{"issue":"8","key":"3225_CR17","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312. https:\/\/doi.org\/10.1097\/00005650-200108000-00006.","journal-title":"Med Care"},{"issue":"4","key":"3225_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3109\/01942638.2011.572148","volume":"31","author":"HL Cintas","year":"2011","unstructured":"Cintas HL, Parks R, Don S, Gerber L. Brief assessment of motor function: content validity and reliability of the upper extremity gross motor scale. Phys Occup Ther Pediatr. 2011;31(4):440\u201350. https:\/\/doi.org\/10.3109\/01942638.2011.572148.","journal-title":"Phys Occup Ther Pediatr"},{"issue":"5","key":"3225_CR19","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1007\/s12325-025-03168-w","volume":"42","author":"KE Moss","year":"2025","unstructured":"Moss KE, Keen R, Fang S, et al. Mobility and quality of life in adults with paediatric-onset hypophosphatasia treated with asfotase alfa: results from UK Managed Access Agreement. Adv Ther. 2025;42(5):2429\u201344. https:\/\/doi.org\/10.1007\/s12325-025-03168-w.","journal-title":"Adv Ther"},{"key":"3225_CR20","unstructured":"Dahir KM, Seefried L, Martos-Moreno G\u00c1, et al. Patient-reported outcomes and quality of life in children and adults with HPP treated with asfotase alfa [abstract]. In: Presented at: joint congress of the European Society for Paediatric Endocrinology and the European Society of Endocrinology, May 10\u201313, 2025, Copenhagen, Denmark."},{"issue":"1","key":"3225_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13023-024-03048-6","volume":"19","author":"PS Kishnani","year":"2024","unstructured":"Kishnani PS, Martos-Moreno G, Linglart A, et al. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Orphanet J Rare Dis. 2024;19(1):109. https:\/\/doi.org\/10.1186\/s13023-024-03048-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3225_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10131","volume":"3","author":"D Phillips","year":"2019","unstructured":"Phillips D, Tomazos IC, Moseley S, et al. Reliability and validity of the 6-minute walk test in hypophosphatasia. JBMR Plus. 2019;3(6): e10131. https:\/\/doi.org\/10.1002\/jbm4.10131.","journal-title":"JBMR Plus"},{"key":"3225_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","volume":"121","author":"PS Kishnani","year":"2019","unstructured":"Kishnani PS, Rockman-Greenberg C, Rauch F, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149\u201362. https:\/\/doi.org\/10.1016\/j.bone.2018.12.011.","journal-title":"Bone"},{"issue":"1","key":"3225_CR24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.dhjo.2013.08.007","volume":"7","author":"J Kim","year":"2014","unstructured":"Kim J, Chung H, Amtmann D, et al. Symptoms and quality of life indicators among children with chronic medical conditions. Disabil Health J. 2014;7(1):96\u2013104. https:\/\/doi.org\/10.1016\/j.dhjo.2013.08.007.","journal-title":"Disabil Health J"},{"key":"3225_CR25","doi-asserted-by":"publisher","first-page":"1138599","DOI":"10.3389\/fendo.2023.1138599","volume":"14","author":"KM Dahir","year":"2023","unstructured":"Dahir KM, Kishnani PS, Martos-Moreno GA, et al. Impact of muscular symptoms and\/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: a cross-sectional analysis from the Global HPP Registry. Front Endocrinol. 2023;14:1138599. https:\/\/doi.org\/10.3389\/fendo.2023.1138599.","journal-title":"Front Endocrinol"},{"key":"3225_CR26","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.metabol.2016.07.006","volume":"65","author":"TJ Weber","year":"2016","unstructured":"Weber TJ, Sawyer EK, Moseley S, Odrljin T, Kishnani PS. Burden of disease in adult patients with hypophosphatasia: results from two patient-reported surveys. Metabolism. 2016;65:1522\u201330. https:\/\/doi.org\/10.1016\/j.metabol.2016.07.006.","journal-title":"Metabolism"},{"issue":"1","key":"3225_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13023-021-01722-7","volume":"16","author":"EI Pierpont","year":"2021","unstructured":"Pierpont EI, Simmons JH, Spurlock KJ, Shanley R, Sarafoglou KM. Impact of pediatric hypophosphatasia on behavioral health and quality of life. Orphanet J Rare Dis. 2021;16(1):80. https:\/\/doi.org\/10.1186\/s13023-021-01722-7.","journal-title":"Orphanet J Rare Dis"},{"key":"3225_CR28","unstructured":"Asfotase alfa for treating paediatric-onset hypophosphatasia. Highly specialised technologies guidance. National Institute for Health and Care Excellence, 2023. www.nice.org.uk\/guidance\/hst23. Accessed 5 Jan 2024."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03225-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03225-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03225-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:16Z","timestamp":1750493656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03225-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3225"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03225-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Raja Padidela: Research grant and honoraria from Alexion, AstraZeneca Rare Disease, Ultragenyx-Mereo, and Bridgebio. Nick Bishop: Investigator for Alexion, AstraZeneca Rare Disease; UK CI for Amgen; CI for Ultragenyx-Mereo; consultant for Amgen, Novo Nordisk, and Rampart; consultant and advisory board participant for Alexion, AstraZeneca Rare Disease, Ultragenyx, and Mereo; research grant from Horizon Europe. Paul Arundel: Principal investigator and advisory board participant with and recipient of honoraria from Alexion, AstraZeneca Rare Disease. Shona Fang and Alexandros Zygouras: Employees of and may own stock\/options in Alexion, AstraZeneca Rare Disease. M. Zulf Mughal: Recipient of honoraria from Alexion, AstraZeneca Rare Disease and Biologix. Nick Shaw: Nothing to disclose. Vrinda Saraff: Investigator for and recipient of honoraria from Alexion, AstraZeneca Rare Disease.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data were collected prospectively from all participants enrolled in the MAA in the UK. All enrolled participants (or their legally authorized representative) were informed of the purpose of the data collection project and the expected use of any data collected. The project complied with all relevant data protection and privacy regulations, including the European Data Protection Act and\/or institution-\/country-specific participant privacy requirements. The project was conducted in accordance with the Declaration of Helsinki. All participants consented to participate in the MAA, including completing questionnaires and attending appointments, and to have their data entered into the MAA database. The program was started in August 2017 and concluded in February 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}